Asset Details
Do you wish to reserve the book?
Real-world safety assessment of burosumab: a pharmacovigilance study utilizing the FDA adverse event reporting system
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Real-world safety assessment of burosumab: a pharmacovigilance study utilizing the FDA adverse event reporting system
Do you wish to request the book?
Real-world safety assessment of burosumab: a pharmacovigilance study utilizing the FDA adverse event reporting system
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Real-world safety assessment of burosumab: a pharmacovigilance study utilizing the FDA adverse event reporting system
2026
Overview
Objective
This study aims to evaluate the adverse events (AEs) associated with burosumab in real-world clinical practice using data from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), and to provide evidence for optimizing its clinical safety management.
Methods
Data for this study were retrieved from the FAERS database via OpenVigil 2.1, covering the period from the first quarter of 2018 to the third quarter of 2024. Disproportionality analyses were performed to quantify adverse event signals associated with burosumab, employing four established methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Multi-Item Gamma Poisson Shrinker (MGPS), and Bayesian Confidence Propagation Neural Network (BCPNN).
Results
A total of 5054 adverse events (AEs) associated with burosumab were identified. Commonly reported AEs included injection site reactions, musculoskeletal pain, restless leg syndrome, skeletal deformities, and corrective orthopedic surgeries necessitated by severe bone deformities. Additionally, several concerning AEs were observed, such as hyperparathyroidism, tertiary hyperparathyroidism, nephrocalcinosis, and dental and periodontal complications.
Conclusion
This study provides an initial evaluation of burosumab’s safety in real-world practice, identifying noteworthy adverse event signals that broaden current understanding and support more informed prescribing decisions for patients with XLH.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
